<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811573</url>
  </required_header>
  <id_info>
    <org_study_id>1407-0041</org_study_id>
    <secondary_id>2019-005037-37</secondary_id>
    <nct_id>NCT04811573</nct_id>
  </id_info>
  <brief_title>A Study in Healthy People to Compare 3 Different Formulations of Apremilast Tablets Taken With or Without Food</brief_title>
  <official_title>Bioequivalence of Three Different Tablet Formulations of 30 mg of Apremilast (EU-sourced Otezla® vs. US-sourced Otezla® vs. Japan-sourced Otezla®) Administered in Healthy Male and Female Subjects in the Fasted State as Well as (for EU-sourced Otezla® vs. US-sourced Otezla®) in the Fed State (an Open-label, Randomised, Single-dose, Five-period, Ten-sequence Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to establish bioequivalence between EU-, US- and Japan-sourced&#xD;
      Otezla® tablet formulations to assure comparability of results from Phase III trials of BI&#xD;
      730357 (new oral agent for treatment of psoriasis as well as other T helper 17 cells&#xD;
      (Th17)-mediated diseases) regardless of whether only the EU-sourced Otezla® or EU and&#xD;
      US-sourced Otezla®/Japan-sourced Otezla® have been used as an active comparator.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to company decision&#xD;
  </why_stopped>
  <start_date type="Actual">March 31, 2021</start_date>
  <completion_date type="Actual">August 18, 2021</completion_date>
  <primary_completion_date type="Actual">August 18, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point)</measure>
    <time_frame>up to 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)</measure>
    <time_frame>up to 48 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum measured concentration of the analyte in plasma)</measure>
    <time_frame>up to 48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Tfasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T: Test Treatment fasted: under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R1: Reference 1 Treatment fasted: under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R2fasted</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R2: Reference 2 Treatment fasted: under fasted conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tfed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T: Test Treatment fed: under fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R1fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R1: Reference 1 Treatment fed: under fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EU-sourced Otezla® (T)</intervention_name>
    <description>Test Treatment (T)</description>
    <arm_group_label>Tfasted</arm_group_label>
    <arm_group_label>Tfed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>US-sourced Otezla® (R1)</intervention_name>
    <description>Reference Treatment (R1)</description>
    <arm_group_label>R1fasted</arm_group_label>
    <arm_group_label>R1fed</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Japan-sourced Otezla® (R2)</intervention_name>
    <description>Reference Treatment (R2)</description>
    <arm_group_label>R2fasted</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male or female subjects according to the assessment of the investigator, as&#xD;
             based on a complete medical history including a physical examination, vital signs&#xD;
             (Blood pressure (BP), Pulse rate (PR)), 12-lead Electrocardiogram (ECG), and clinical&#xD;
             laboratory tests&#xD;
&#xD;
          -  Age of 18 to 55 years (inclusive)&#xD;
&#xD;
          -  Body mass index (BMI) of 18.5 to 29.9 kg/m2 (inclusive)&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with Good Clinical Practice (GCP) and local legislation&#xD;
&#xD;
          -  Male subjects, or female subjects who meet any of the following criteria for a highly&#xD;
             effective contraception from at least 30 days before the first administration of trial&#xD;
             medication until 30 days after trial completion:&#xD;
&#xD;
               -  Use of combined (estrogen and progestogen containing) hormonal contraception that&#xD;
                  prevents ovulation (oral, intravaginal or transdermal), plus condom&#xD;
&#xD;
               -  Use of progestogen-only hormonal contraception that inhibits ovulation (only&#xD;
                  injectables or implants), plus condom&#xD;
&#xD;
               -  Use of intrauterine device (IUD) or intrauterine hormone-releasing system (IUS)&#xD;
&#xD;
               -  A vasectomised sexual partner (vasectomy at least 1 year prior to enrolment)&#xD;
&#xD;
               -  Surgically sterilised (including hysterectomy or bilateral occlusion)&#xD;
&#xD;
               -  Postmenopausal, defined as no menses for 1 year without an alternative medical&#xD;
                  cause (in questionable cases a blood sample with levels of Follicle-stimulating&#xD;
                  hormone (FSH) above 40 U/L and estradiol below 30 ng/L is confirmatory)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator&#xD;
&#xD;
          -  Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 45 to 90 bpm&#xD;
&#xD;
          -  Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance&#xD;
&#xD;
          -  Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          -  Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair)&#xD;
&#xD;
          -  Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells, or blackouts Further&#xD;
             exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Humanpharmakologisches Zentrum Biberach</name>
      <address>
        <city>Biberach</city>
        <zip>88397</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Apremilast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

